$SMMT News

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Summit Therapeutics Stock Climbs Wednesday: What's Happening?

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43

Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab

AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies